Baudax Bio Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.21
Dividend & YieldN/A$ (N/A)
Beta 1.55
Market capitalization 2.79M
Operating cash flow -36.66M
ESG Scores unknown

Company description

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio1.18
Working Capital-2.52
Return On Equity-1.49
Debt To Equity0.48
Fixed Asset Ratio0.58
Fixed Interest Cover-22.74

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 493k -8.99M 4.47M -1.49M
Total Cashflows From Investing Activities -3.45M -1.48M -639k -194k
Net Borrowings 10.04M 10.04M 10.04M
Total Cash From Financing Activities 63.2M 69.27M 57.3M 35.01M
Change To Operating Activities -46k 117k -804k 921k
Issuance Of Stock 63.2M 79.27M 51.29M 42.98M
Net Income -73.67M -32.56M -76.1M -19.77M
Change In Cash 17.74M 17.74M 12.6M -14.45M
Effect Of Exchange Rate
Total Cash From Operating Activities -59.75M -50.04M -44.06M -49.27M
Depreciation 396k 480k 408k 240k
Change To Account Receivables -51k -51k -51k -491k
Other Cashflows From Financing Activities -10M -10M -3.56M -7.87M
Change To Netincome 13.07M -9.09M 28.86M -29.24M
Capital Expenditures -3.37M -1.32M -639k -203k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 35.58M 17.26M 9.09M 3.12M
Income Before Tax -73.67M -32.56M -76.1M -19.77M
Net Income -73.67M -32.56M -76.1M -19.77M
Selling General Administrative 29.45M 22.61M 43.34M 45.31M
Gross Profit -1.24M -1.36M
Ebit -65.04M -39.87M -55.81M -52.38M
Operating Income -65.04M -39.87M -55.81M -52.38M
Interest Expense -1.36M -1.36M -1.36M -2.3M
Income Tax Expense
Total Revenue 493k 1.08M
Cost Of Revenue 1.73M 2.44M
Total Other Income ExpenseNet -8.63M 7.32M -20.29M 32.61M
Net Income From Continuing Ops -73.67M -32.56M -76.1M -19.77M
Net Income Applicable To Common Shares -73.67M -32.56M -76.1M -22.19M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 103.37M 70.93M 83.53M 40.05M
Total Stockholder Equity -68.35M -16.72M -14.8M 13.23M
Other Current Liabilities 15.08M 4.14M 9.45M 6.74M
Total Assets 35.02M 54.21M 68.73M 53.28M
Common Stock -68.35M 94k 487k 983k
Other Current Assets
Retained Earnings -36.22M -112.32M -132.09M
Treasury Stock
Cash 17.74M 30.34M 15.89M
Total Current Liabilities 22.78M 7.71M 18.13M 15.65M
Other Stockholder Equity
Property, Plant, and Equipment 3.98M 5.55M 5.05M 5.01M
Total Current Assets 2.51M 20.14M 36.72M 23.49M
Net Tangible Assets -96.87M -45.25M -41.18M -10.58M
Net Receivables 51k 542k
Accounts Payable 2.65M 271k 3.65M 1.47M


Insider Transactions

Here are the insider transactions of stock shares related to Baudax Bio Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
WEISMAN WAYNE BStock Award(Grant) at price 0.00 per share.D2022-06-15Director39.47k
HENWOOD GERALDINE AStock Award(Grant) at price 0.00 per share.D2022-06-15Chief Executive Officer39.47k
CHURCHILL WINSTON J. JR.Stock Award(Grant) at price 0.00 per share.D2022-06-15Director39.47k
DRECHSLER ANDREW TStock Award(Grant) at price 0.00 per share.D2022-06-15Director39.47k
ASHTON WILLIAM LStock Award(Grant) at price 0.00 per share.D2022-06-15Director39.47k
BASKIES ARNOLD MStock Award(Grant) at price 0.00 per share.D2022-06-15Director39.47k
DILMORE JILLIANStock Award(Grant) at price 0.00 per share.D2022-06-15Officer15.47k
HENWOOD GERALDINE APurchase at price 0.59 per share.D2021-09-22Chief Executive Officer8.2k
CHURCHILL WINSTON J. JR.Purchase at price 0.63 per share.D2021-08-31Director100k
CASTEN RICHARD SPurchase at price 0.51 per share.D2021-08-20Chief Financial Officer50k
CHURCHILL WINSTON J. JR.Purchase at price 0.78 per share.D2021-06-07Director25k
CASTEN RICHARD SPurchase at price 0.79 per share.D2021-05-14Chief Financial Officer25k
BASKIES ARNOLD MPurchase at price 0.82 per share.D2021-05-11Director10k
HENWOOD GERALDINE APurchase at price 0.83 per share.D2021-05-07Chief Executive Officer6k
WEISMAN WAYNE BD2021-04-07Director56.45k
CHURCHILL WINSTON J. JR.D2021-04-07Director56.45k
ALTOMARI ALFREDD2021-04-07Director56.45k
DRECHSLER ANDREW TD2021-04-07Director56.45k
ASHTON WILLIAM LD2021-04-07Director56.45k
BASKIES ARNOLD MD2021-04-07Director56.45k
CASTEN RICHARD SPurchase at price 1.41 per share.D2021-03-15Chief Financial Officer25k
CASTEN RICHARD SD2021-03-08Chief Financial Officer100k
HENWOOD GERALDINE AD2021-01-20Chief Executive Officer65.44k
LAKE RYAN DAVIDD2021-01-15Chief Financial Officer25k
ALTOMARI ALFREDPurchase at price 1.06 per share.D2020-11-23Director5k
DRECHSLER ANDREW TD2020-08-20Director20k
BASKIES ARNOLD MD2020-08-20Director20k
WEISMAN WAYNE BD2020-05-06Director22.95k
CHURCHILL WINSTON J. JR.D2020-05-06Director22.95k
ALTOMARI ALFREDD2020-05-06Director22.95k
ASHTON WILLIAM LD2020-05-06Director22.95k
WEISMAN WAYNE BPurchase at price 2.29 per share.D2020-03-26Director10k
CHURCHILL WINSTON J. JR.Purchase at price 2.28 - 2.44 per share.D/I2020-03-26Director31.5k
ALTOMARI ALFREDPurchase at price 2.34 per share.D2020-03-26Director5k
HENWOOD GERALDINE AD2020-01-27Chief Executive Officer19.07k
LAKE RYAN DAVIDD2020-01-27Chief Financial Officer6k
WEISMAN WAYNE BD2019-12-05Director20k
HENWOOD GERALDINE AD2019-12-05Chief Executive Officer323.96k
CHURCHILL WINSTON J. JR.D2019-12-05Director20k
ALTOMARI ALFREDD2019-12-05Director20k
LAKE RYAN DAVIDD2019-12-05Chief Financial Officer82.53k
ASHTON WILLIAM LD2019-12-05Director20k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Baudax Bio Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Baudax Bio Inc

Here is the result of two systematic investment strategies applied to Baudax Bio Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Baudax Bio Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Baudax Bio Inc:

Baudax Bio Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -53.87% on the backtest period.

Performance at glance

Performance

-53.87 %

Latent gain

-536.77 $

Invested capital

996.44 $

Annualized return

-26.41 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Baudax Bio Inc

This is the result of two momentum investment strategies applied to Baudax Bio Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Baudax Bio Inc

The following chart shows all the entries opened by the momentum investment system on Baudax Bio Inc:

Baudax Bio Inc momentum entries
  • The first momentum investment strategy would give -60.06% of return on Baudax Bio Inc. That represents -1199.59$ of latent gain with 1997.38$ of employed capital.
  • The second momentum investment strategy would give -55.07% of return on Baudax Bio Inc. That represents -826.92$ of latent gain with 1501.57$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-60.06 %

Latent gain

-1199.59 $

Invested capital

1997.38 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-55.07 %

Latent gain

-826.92 $

Invested capital

1501.57 $

Annualized return

-35.3 %

Momentum equity curve on Baudax Bio Inc

The following chart shows the equity curve of the two momentum strategies applied to Baudax Bio Inc:

Baudax Bio Inc momentum equity

Note: the dividends potentially given by Baudax Bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Baudax Bio Inc

The following chart shows the employed capital evolution of the two momentum strategies on Baudax Bio Inc since the beginning:

Baudax Bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Baudax Bio Inc

Buy the dip entry openings on Baudax Bio Inc

Baudax Bio Inc

The performance achieved by the robo-advisor on Baudax Bio Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Baudax Bio Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Baudax Bio Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Baudax Bio Inc

The following chart shows the result of the investment strategy applied to Baudax Bio Inc:

Baudax Bio Inc

Note: the dividends potentially given by Baudax Bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Baudax Bio Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Baudax Bio Inc:

Baudax Bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Baudax Bio Inc

In this section, I will compare the three previous investment strategies applied to Baudax Bio Inc.

Equity curve comparison on Baudax Bio Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Baudax Bio Inc investment strategy comparison

Employed capital comparison on Baudax Bio Inc

Baudax Bio Inc investment comparison

Performance comparison on Baudax Bio Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -53.87% -536.77$ 996.44$ -26.41%
Momentum 1 quarter -60.06% -1199.59$ 1997.38$ -33.37%
Momentum 2 quarters -55.07% -826.92$ 1501.57$ -35.3%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-26.41 %

Momentum 1Q

-35.3 %

Momentum 2Q

-35.3 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Baudax Bio Inc:

Positive correlations

Most correlated stocks this year

  • Baudax Bio Inc

  • Most correlated stocks last 3 months

  • Méthanor SCA
  • Baudax Bio Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Ranpak Holdings Corp - Class A
  • BlackRock Municipal 2030 Target Term Trust

  • Note: The algorithm computes the probability of correlation between Baudax Bio Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Baudax Bio Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Baudax Bio Inc
    Country United States
    City Malvern
    Address 490 Lapp Road
    Phone 484 395 2440
    Website www.baudaxbio.com
    FullTime employees 80
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker BXRX
    Market www.nasdaq.com

    Baudax Bio Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown